Crenae Therapeutics is focused on the development of anti-ASPH therapeutics for the treatment of metastatic cancer. ASPH inhibitors are non-toxic, orally bioavailable, Notch pathway modulators without dose limiting GI toxicity like previous Notch therapeutics. A robust IP portfolio, including small molecules, antibody diagnostics and therapeutics, and backup chemotypes provides a strong IP foundation for developing anti-ASPH therapeutics. Target cancers include veterinary, human orphan cancers such as cholangiocarcinoma and fibrolamellar hepatocellular carcinoma, and large market cancers including lung, hepatocellular carcinoma, breast, pancreatic, gastric and colon cancers.
Company Details
- Employees
- 1
- Founded
- -
- Address
- 39925 N. Pride Dr., Phoenix,arizona 85086,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Phoenix, Arizona
- Competitors
Crenae Therapeutics Questions
Crenae Therapeutics's website is https://crenaetherapeutics.godaddysites.com/
Crenae Therapeutics's LinkedIn profile is https://www.linkedin.com/company/crenae-therapeutics
Crenae Therapeutics has
1 employees.
View email and phone details for 1
employees at Crenae Therapeutics.
Crenae Therapeutics's industry is
Biotechnology Research
Crenae Therapeutics's categories are Biotechnology Research
Crenae Therapeutics's founding year is 2017
